MoleCure is discovering small-molecule antagonists that block the assembly of the LIF / LIFR / gp130 signaling complex — a trimeric complex that activates the JAK/STAT pathway. Aberrant LIFR signaling drives tumor progression, therapy resistance, and poor survival in pancreatic ductal adenocarcinoma (PDAC), making it a compelling therapeutic target.
American Cancer Society, Cancer Facts & Figures.
The global pancreatic cancer therapeutics market is large and growing rapidly — independent analyst estimates place it in the range of roughly USD 2.7–2.9 billion as of 2024, with projected growth at a 12–16% CAGR over the next decade.
Market sizing varies by source and methodology.
U.S. orphan drug designation for pancreatic cancer offers incentives including market exclusivity, tax credits, and FDA fee waivers — reducing development risk. LIFR signaling is implicated across multiple cancers (breast, liver, prostate and others), giving the approach potential breadth beyond PDAC.
Current efforts against this pathway include antibodies, ligand traps, and repurposed compounds. MoleCure is differentiated by a small-molecule approach that targets two protein–protein interaction sites simultaneously, enabled by a fragment-based and AI-augmented discovery platform.
Founder
Founder & CEO
Peter Pallai is the Founder and CEO of MoleCure Therapeutics. Previously CEO of BioBlocks, Inc. for over 20 years, where he built an internationally recognized medicinal chemistry organization and a lead-discovery platform. He has led medicinal chemistry teams at ArQule, Inc. and Procept, Inc., and served as a Section Head at Boehringer Ingelheim, directing research programs in antiviral and immunology areas. He is widely recognized for his work in fragment-based lead discovery (FBLD) and small-molecule inhibitor design.
Advisor
American Cancer Society Professor, Molecular and Cell Biology Laboratory, Salk Institute; Renato Dulbecco Chair in Cancer Research and Deputy Director of the Salk Institute Cancer Center.
Established the role of LIF signaling in PDAC tumorigenesis.
Advisor
Head, Medicinal Chemistry Research Group, Research Centre for Natural Sciences (HUN-REN RCNS), Hungary.
Developed the hot-spot identification and fragment-pharmacophore methods used in the platform.
Reach out about partnership, collaboration, or research questions.
Or email us directly at peter@molecuretherapeutics.com.